CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 258 enrolled
Drug / intervention
Glycopyrrolate 0.2 MG/ML +1 moredrug
Likely dose
Glycopyrrolate 0.2 MG/MLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04401345
NCT04401345Phase 4Completed
CompareCT.gov

Effect of Glycopyrrolate on Vasopressors Requirement for Non-elective Caesarean Section Under Spinal Anaesthesia

Rajesh Deshar·interventional·Posted May 26, 2020·Updated Feb 21, 2021

In Brief

A Phase 4 clinical trial evaluating Glycopyrrolate 0.2 MG/ML and Normal saline for Glycopyrrolate and 3 related conditions. Completed, enrolled 258 participants across 1 site.

Detailed Summary

This is prospective randomised double blind study conducted in parturients planned for non-elective caesarean section under spinal anaesthesia. Glycopyrrolate group will receive 0.2 mg of Glycopyrrolate before start of phenylephrine infusion. Control group will receive 0.2 ml of Normal Saline before start of phenylephrine infusion. Total amount of vasopressors required i.e. ephedrine or phenylephrine will recorded in the form of phenylephrine equivalent during intraoperative period.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlycopyrrolate, Post-spinal Hypotension, Effect of Drug, Hemodynamic Instability
CountriesNepal
Collaborators--

Timeline

Phase 4CompletedFinished
202120222023202420252026
First PostedMay 26, 2020
Enrollment StartJun 1, 2020
Primary CompletionJan 31, 2021
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 6.1 years ago

Interventions

Glycopyrrolate 0.2 MG/MLdrug

In this group, the patients will receive glycopyrrolate 0.2 mg in 1 ml

Normal salinedrug

In this group, the patients will receive 1 ml of 0.9% normal saline